Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription 12.10.2026 2 Acta Haematol 1 Am J Hematol 6 Blood 1 Bone Marrow Transplant 2 Br J Cancer 1 Cancer 2 Cancer Lett 1 Cancer Res 3 Eur J Haematol 1 Eur J Immunol 1 Exp Hematol 1 Genes Chromosomes Cancer 5 Int J Hematol 1 J Biol Chem 1 J Pediatr Hematol Oncol 1 Leuk Lymphoma 4 Leuk Res 8 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. FIRESTONE RA, Palecki J, Rosenberg M, Chen J, et al
   Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.
   Acta Haematol. 2026 Oct 7:1. doi: 10.1159.
   PubMed         Abstract available
   
   
2. SEDAKI B, Iat A, Benachour S, Loschi M, et al
   Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial.
   Acta Haematol. 2026;149:493-497.
   PubMed         Abstract available
   
   

   
   Am J Hematol

3. FILENI C, Chiche E, Swoboda D, Coltoff A, et al
   Oral Azacitidine Maintenance After CPX-351 in Transplant-Ineligible Patients With Therapy-Related or Myelodysplasia-Related Acute Myeloid Leukemia.
   Am J Hematol. 2026 Oct 9. doi: 10.1002/ajh.70521.
   PubMed        
   
   

   
   Blood

4. 
   Muffly L, Frey NV, Roloff GW, et al. Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026;148(6):657-668.
   Blood. 2026;148:1941.
   PubMed        
   
   
5. JEBARAJ BMC, Tausch E, Yosifov DY, Schneider C, et al
   Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.
   Blood. 2026 Oct 6:blood.2025032302. doi: 10.1182/blood.2025032302.
   PubMed         Abstract available
   
   
6. KENNEDY E, Stott L, Ashworth I, Ladikou E, et al
   TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.
   Blood. 2026 Oct 5:blood.2025032914. doi: 10.1182/blood.2025032914.
   PubMed         Abstract available
   
   
7. TAM CS, Seymour JF, Blombery P
   Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era.
   Blood. 2026 Oct 5:blood.2026033293. doi: 10.1182/blood.2026033293.
   PubMed         Abstract available
   
   
8. ZHONG X, Roberts KG, Wei H, Sun Z, et al
   Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
   Blood. 2026 Oct 5:blood.2026033793. doi: 10.1182/blood.2026033793.
   PubMed         Abstract available
   
   
9. GIL JV, Sargas C, Ayala R, Gutierrez NC, et al
   Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.
   Blood. 2026;148:1911-1924.
   PubMed         Abstract available
   
   

   
   Bone Marrow Transplant

10. RUGGIU M, Gournay V, Labussiere H, Carre M, et al
    Auto-immune diseases associated with myelodysplastic syndrome and chronic myelomonocytic leukemia do not impact allogenic transplantation outcomes.
    Bone Marrow Transplant. 2026 Oct 6. doi: 10.1038/s41409-026-03065.
    PubMed        
    
    

    
    Br J Cancer

11. OZCAN SG, Stanko C, Szymanski L, Fischer M, et al
    Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.
    Br J Cancer. 2026;135:1196-1206.
    PubMed         Abstract available
    
    
12. KARAKULAK T, Moch H, von Mering C, Kahraman A, et al
    Switches in alternatively spliced isoforms impact protein and drug interactions in melanoma, ovarian cancer, and acute myeloid leukemia.
    Br J Cancer. 2026 Oct 3. doi: 10.1038/s41416-026-03638.
    PubMed         Abstract available
    
    

    
    Cancer

13. DAVER NG, Zeidan AM, Stein AS, Zeidner JF, et al
    Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPalpha-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.
    Cancer. 2026;132:e70626.
    PubMed         Abstract available
    
    

    
    Cancer Lett

14. JIN Y, An ZY, Zhao P, Fu HX, et al
    GAMMA: A genetic-clinical prognostic model for risk stratification in patients with relapsed/refractory acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation.
    Cancer Lett. 2026 Oct 8:218883. doi: 10.1016/j.canlet.2026.218883.
    PubMed         Abstract available
    
    
15. BENETTON M, Da Ros A, Peloso A, Longo G, et al
    Reactive oxygen species define leukemia stem cell identity in pediatric acute myeloid leukemia.
    Cancer Lett. 2026 Oct 4:218866. doi: 10.1016/j.canlet.2026.218866.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. ZHANG L, Fu YH, Hua WK, Chen YC, et al
    The HDAC8-U2AF1 Axis Dysregulates DNA Damage-Responsive RNA Splicing and Creates Targetable Vulnerabilities in Acute Myeloid Leukemia.
    Cancer Res. 2026 Oct 8. doi: 10.1158/0008-5472.CAN-25-5027.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

17. STEINER L, Silva-Bermudez LS, Ghazal M, Abba M, et al
    Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.
    Eur J Haematol. 2026;117:1358-1368.
    PubMed         Abstract available
    
    
18. HU J, Shuai X, Guo Y, Gong Y, et al
    Prognostic Validation of IPSS-M Versus ELN 2022/2024 in MDS/AML Patients: A Survival and Treatment Response Analysis.
    Eur J Haematol. 2026;117:1309-1317.
    PubMed         Abstract available
    
    
19. MA Y, Jiang Y, Wang L, Cheng Y, et al
    ARHGEF2::JAK2 Fusion Drives Leukemogenesis via CCNB1-Dependent Signaling.
    Eur J Haematol. 2026;117:1238-1248.
    PubMed         Abstract available
    
    

    
    Eur J Immunol

20. DRAGO R, Prete RD, Bartolini G, Gazziero VA, et al
    Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro.
    Eur J Immunol. 2026;56:e70289.
    PubMed         Abstract available
    
    

    
    Exp Hematol

21. METODIEVA A, Karbanova J, Chiriches C, Mian AA, et al
    Prominin-1 (CD133) is essential for the determination of the phenotype of Philadelphia chromosome-positive leukemia.
    Exp Hematol. 2026 Oct 6:105918. doi: 10.1016/j.exphem.2026.105918.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

22. HEUSLER C, Hildebrandt B, Schulz F, Nachtkamp K, et al
    Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML.
    Genes Chromosomes Cancer. 2026;65:e70177.
    PubMed         Abstract available
    
    

    
    Int J Hematol

23. YOKOYAMA H
    Recent advances in cell therapy for AML/MDS.
    Int J Hematol. 2026;124:453-455.
    PubMed         Abstract available
    
    
24. AKATSUKA Y
    Current status and challenges of TCR-T cell therapy for AML/MDS.
    Int J Hematol. 2026;124:486-494.
    PubMed         Abstract available
    
    
25. WAKAYAMA T, Imoto N, Ukai S, Ito R, et al
    Prognostic impact of WT1 dynamics in peripheral blood before and after allogeneic HSCT in patients with AML and MDS.
    Int J Hematol. 2026;124:568-579.
    PubMed         Abstract available
    
    
26. SUGA M, Hosen N
    Recent advances in CAR T and CAR NK cell therapy for AML.
    Int J Hematol. 2026;124:470-477.
    PubMed         Abstract available
    
    
27. CHANG YH, Goyama S
    Recent advances of cell therapies for AML/MDS: exploring the therapeutic potential of innate immune cells in AML/MDS.
    Int J Hematol. 2026;124:478-485.
    PubMed         Abstract available
    
    

    
    J Biol Chem

28. HARWARDT J, Pudewell S, Keil K, Lipinski B, et al
    LIF and let die: Generation, mechanistical and structural characterization of bispecific antibodies triggering leukemia inhibitory factor (LIF) receptor activation independent of the cytokine LIF.
    J Biol Chem. 2026 Oct 9:113634. doi: 10.1016/j.jbc.2026.113634.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

29. YUZUGULDU B, Krieger M, Comella-Higgins J, Mohamed A, et al
    Urolithiasis in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (ALL/LLy): A Single-Center Case Series of Clinical, Metabolic, and Imaging Features.
    J Pediatr Hematol Oncol. 2026 Oct 9. doi: 10.1097/MPH.0000000000003301.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

30. DE LA GARZA-SALAZAR F, Lankenau Vela DL, Munoz Cruz DG
    Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2026 Oct 7:1-17. doi: 10.1080/10428194.2026.2742608.
    PubMed         Abstract available
    
    

    
    Leuk Res

31. BOUSSI L, El Marabti E, Shaffer B, Landau H, et al
    Mini-hyper-CVD with low-dose inotuzumab ozogamicin is an effective induction strategy for adults with immunomodulatory drug-associated B-cell acute lymphoblastic leukemia.
    Leuk Res. 2026;171:108331.
    PubMed        
    
    
32. ALLEN C, Zale A, Ghiaur G, Ambinder A, et al
    Timing of ATRA in acute promyelocytic leukemia: When location of presentation alters patient outcomes.
    Leuk Res. 2026;171:108333.
    PubMed        
    
    
33. CHENG J, Wei N, Lu Y, Gu J, et al
    Luvometinib as a salvage therapy for a patient with PTPN11-positive juvenile myelomonocytic leukemia.
    Leuk Res. 2026;171:108329.
    PubMed        
    
    
34. MOJIDRA R, Kumari S, Gardi N, Thomas D, et al
    Functional substitution of imatinib-inactivated canonical oncoprotein BCR::ABL1 by overexpressed PLAG1 results in BCR::ABL1-independent resistance in blast phase of chronic myeloid leukemia.
    Leuk Res. 2026;171:108339.
    PubMed         Abstract available
    
    

    
    Leukemia

35. FUJITA M, Ureshino H, Kimura S
    Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort.
    Leukemia. 2026 Oct 6. doi: 10.1038/s41375-026-03155.
    PubMed         Abstract available
    
    
36. GANG M, Gale RP, Walter RB
    Recombinant hematopoietic growth factors in acute myeloid leukemia.
    Leukemia. 2026 Oct 5. doi: 10.1038/s41375-026-03158.
    PubMed        
    
    
37. U NIEMANN C, Munir T, Owen C, Follows G, et al
    First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.
    Leukemia. 2026 Oct 2. doi: 10.1038/s41375-026-03150.
    PubMed         Abstract available
    
    
38. CHOI MY, Ghia EM, Siddiqi T, Barrientos JC, et al
    Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.
    Leukemia. 2026 Oct 2. doi: 10.1038/s41375-026-03131.
    PubMed         Abstract available
    
    
39. ASPAS REQUENA G, Aguiar E, Brioso J, Ayala R, et al
    Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.
    Leukemia. 2026 Oct 6. doi: 10.1038/s41375-026-03154.
    PubMed         Abstract available
    
    
40. PAIVA B, Burgos L, Gonzalez C, Ahdadi A, et al
    Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.
    Leukemia. 2026 Oct 8. doi: 10.1038/s41375-026-03153.
    PubMed         Abstract available
    
    
41. HEIN N, Poh P, Powell JA, Nunez Villacis L, et al
    Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.
    Leukemia. 2026 Oct 8. doi: 10.1038/s41375-026-03148.
    PubMed         Abstract available
    
    
42. PARK J, Kim SH, Park J, Park H, et al
    Correction: BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.
    Leukemia. 2026 Oct 9. doi: 10.1038/s41375-026-03166.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum